Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cincinnati
• Collaborators: National Institute on Drug Abuse (NIDA); University of Colorado, Denver
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• Meet Diagnostic and Statistical Manual for Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria for ADHD

• Meet DSM-IV diagnostic criteria for at least one non-nicotine substance use disorder

• Has a DSM-IV ADHD Symptom Checklist score ≥ 22 derived from the adolescent-completed checklist

Exclusion Criteria:

• Serious medical illness

• History of tic disorder

• Pregnant or breastfeeding

• Meet DSM-IV criteria for current or life-time psychotic disorder

• Meet DSM-IV criteria for current or life-time bipolar disorder

• Requires/or prescribed other concurrent psychotropic medication

• Taking any medications that may produce interactions with OROS-MPH

• Opiate dependence

• Methamphetamine abuse or dependence

• Suicidal risk

• Enrolled in an inpatient, residential, day treatment, or outpatient substance abuse program within 28 days prior to signing consent